Home > Resources > Whitepapers > Biopreservation Best Practices: A Cornerstone in the Supply Chain of Cell-based Therapies – MSC Model Case Study

Biopreservation Best Practices: A Cornerstone in the Supply Chain of Cell-based Therapies – MSC Model Case Study

December 18, 2017

Mesenchymal stromal cells (MSCs) are prime candidates for regenerative medicine and therapeutic applications due to both their potent immuno-modulatory function and a unique ability to proliferate and differentiate into a variety of cell lineages. However, the stresses incurred during bio preservation /stability intervals (non-frozen and cryopreserved), including transit to and from the clinic can render MSCs ineffective and potentially unsafe. Challenges related to the formulation, transportation, distribution and delivery of source material (tissue, blood, marrow) and MSC-based products are important and inter-related components of the supply chain and scale-up. Effective bio preservation can optimize the quality of cell/tissue source material and final cell/tissue products, mitigate the adverse effects of interruptions and unforeseen events throughout the supply chain, as well as support the return to function of MSCs following patient administration.

Spotlight

Intellia Therapeutics, Inc.

Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

OTHER WHITEPAPERS

Bioanalytical Techniques to Advance Biosimilars Development

whitePaper | August 22, 2022

Biosimilar therapies offer more unique approaches to treating patients with serious diseases, such as cancer.

Advancing Diversity in Clinical Development through Cross-Stakeholder Commitment and Action

whitePaper | November 10, 2022

The call for achieving representative diversity in clinical trials and development programs is not new and indeed dates back more than five decades in the United States but has been amplified over the course of the COVID-19

Osmolality monitoring for UF/DF and CEXcapture of mAbs from mammalian cell cultures

whitePaper | July 25, 2022

The goal of each process step is to facilitate the production of a consistent product with high yield, quality, purity, and functionality. Throughout each step various Process Analytical Tools (PAT) are used to ensure quality and production metrics are maintained.

State of the Global Biotech Landscape: Where the Opportunities Lie

whitePaper | December 13, 2022

Over the last five years, the global biotech and pharmaceutical landscape has witnessed continued growth. The analysis period (2017-2022) encompasses a unique timeframe including the global COVID-19 pandemic.

Cell and Gene Therapy Clinical Trials

whitePaper | November 8, 2022

Using experienced-based best practices and documented tools, ICON has conducted over 63 CGT trials across multiple therapeutic areas from haematology-oncology torare and orphan diseases.

DIGITAL BIOTECH IS MISSION-CRITICAL TO MODERNA

whitePaper | May 20, 2022

We are living in a unique time in which the world is changing faster than ever. This largely is due to an influx and infusion of digital technologies that are reinventing and reimagining businesses across nearly every sector, and dramatically shifting societal and economic interactions. While the life science industry has, to some extent, adopted various digital technologies, it has not had a significant digital transformation in how it does business.

Spotlight

Intellia Therapeutics, Inc.

Events

8th International Conference on Bio-Sensing Technology

Conference

8th International Conference on Bio-Sensing Technology

Conference